Disclosed is the use of (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1h-pyrazol-4-yl)-pyridin-2-ylamine as depicted or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the therapeutic treatment of abnormal cell growth in a mammal in need of such treatment. Wherein the abnormal cell growth is mediated by anaplastic lymphoma kinase (ALK).
